Thinly traded Aprea Therapeutics (APRE -0.2%) announces Breakthrough Therapy status
in the U.S. for lead candidate APR-246, combined with chemo agent
azacitidine, for the treatment of myelodysplastic syndromes (MDS) with a
susceptible TP53 mutation.
A Phase 2 study
evaluating the combo as maintenance therapy after allogeneic
hematopoietic stem cell transplant in patients with TP53-mutant MDS or
AML is in process with an estimated primary completion date in July
2021.
The company says small molecule APR-246 reactivates the mutant form of the tumor suppressor protein p53.
https://seekingalpha.com/news/3536374-aprea-therapeutics-nabs-accelerated-review-status-in-u-s-for-aprminus-246
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.